Royal London Asset Management Ltd. Acquires 5,733 Shares of DexCom, Inc. (NASDAQ:DXCM)

Royal London Asset Management Ltd. increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 163,238 shares of the medical device company’s stock after acquiring an additional 5,733 shares during the period. Royal London Asset Management Ltd.’s holdings in DexCom were worth $10,943,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Motley Fool Asset Management LLC grew its holdings in shares of DexCom by 168.7% in the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock valued at $17,993,000 after acquiring an additional 171,150 shares in the last quarter. Motley Fool Wealth Management LLC grew its holdings in shares of DexCom by 157.1% in the third quarter. Motley Fool Wealth Management LLC now owns 295,856 shares of the medical device company’s stock valued at $19,834,000 after acquiring an additional 180,775 shares in the last quarter. Investment Management Corp of Ontario grew its holdings in DexCom by 51.8% during the third quarter. Investment Management Corp of Ontario now owns 13,194 shares of the medical device company’s stock valued at $885,000 after purchasing an additional 4,500 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in DexCom by 660.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 34,609 shares of the medical device company’s stock valued at $2,320,000 after purchasing an additional 30,058 shares during the period. Finally, Ascent Group LLC increased its position in DexCom by 7.9% in the third quarter. Ascent Group LLC now owns 7,950 shares of the medical device company’s stock worth $533,000 after buying an additional 583 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

NASDAQ DXCM opened at $77.72 on Friday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a market capitalization of $30.36 billion, a P/E ratio of 46.54, a P/E/G ratio of 2.48 and a beta of 1.12. The company has a fifty day moving average of $72.55 and a 200-day moving average of $86.05.

Wall Street Analyst Weigh In

DXCM has been the subject of several research reports. Leerink Partners cut their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Stifel Nicolaus upped their price target on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, August 23rd. Oppenheimer reduced their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,431 shares of company stock valued at $399,319. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.